Advertisement

ADVERTISEMENT

Jordan Kadish

News
Tafasitamab Plus R-CHOP With or Without Lenalidomide Yields Encouraging Efficacy, Manageable Safety Among Patients With Untreated DLBCL
11/28/2023
A combination of tafasitamab plus R-CHOP with or without the addition of lenalidomide demonstrated encouraging efficacy and manageable safety among patients with untreated diffuse large B-cell lymphoma, according to study results.
A combination of tafasitamab plus R-CHOP with or without the addition of lenalidomide demonstrated encouraging efficacy and manageable safety among patients with untreated diffuse large B-cell lymphoma, according to study results.
A combination of tafasitamab...
11/28/2023
Oncology
News
Disease Outcomes Among Real-World Patients With Relapsed and Triple-Class Refractory Multiple Myeloma
01/26/2024
Real-world findings showed that disease outcomes are unfavorable among patients with relapsed and triple-class refractory multiple myeloma following standard-of-care treatment, demonstrating an unmet need for the development of novel...
Real-world findings showed that disease outcomes are unfavorable among patients with relapsed and triple-class refractory multiple myeloma following standard-of-care treatment, demonstrating an unmet need for the development of novel...
Real-world findings showed that...
01/26/2024
Oncology
Conference Coverage
Abiraterone Plus Olaparib Prolonged rPFS, Improved OS Among Patients With Castration-Resistant Prostate Cancer
02/17/2023
According to results presented at the 2023 ASCO GU Cancers Symposium, the randomized, double-blind, phase 3 PROpel study found abiraterone acetate plus olaparib prolonged radiographic progression-free survival and improved overall survival...
According to results presented at the 2023 ASCO GU Cancers Symposium, the randomized, double-blind, phase 3 PROpel study found abiraterone acetate plus olaparib prolonged radiographic progression-free survival and improved overall survival...
According to results presented...
02/17/2023
Oncology
News
Interleukin-22 Dimer F-652 Plus Systemic Corticosteroids Demonstrated High Response Rate Among Patients With Acute GVHD
06/06/2023
Results from a phase 2 study showed that interleukin-22 dimer, F-652, plus systemic corticosteroids demonstrated high response rates among patients with newly diagnosed lower gastrointestinal acute GVHD.
Results from a phase 2 study showed that interleukin-22 dimer, F-652, plus systemic corticosteroids demonstrated high response rates among patients with newly diagnosed lower gastrointestinal acute GVHD.
Results from a phase 2 study...
06/06/2023
Oncology
News
Clinical Outcomes After BTK Inhibitor and B-Cell Lymphoma 2 Inhibitor Treatment Among Patients With CLL
06/08/2023
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates...
06/08/2023
Oncology
News
Pirtobrutinib Demonstrated Durable Efficacy, Safety Among Patients With Covalent BTK Inhibitor-Pretreated MCL
09/18/2023
According to the BRUIN trial, pirtobrutinib demonstrated encouraging efficacy and safety outcomes among patients with heavily pretreated mantle cell lymphoma following covalent BTK inhibitor treatment.
According to the BRUIN trial, pirtobrutinib demonstrated encouraging efficacy and safety outcomes among patients with heavily pretreated mantle cell lymphoma following covalent BTK inhibitor treatment.
According to the BRUIN trial,...
09/18/2023
Oncology
News
Ibrutinib Plus Rituximab Demonstrates Efficacy as Second-Line Treatment for Patients With CLL and R/R AIHA/PRCA
09/21/2023
A phase 2 trial found that ibrutinib plus rituximab demonstrated efficacy among patients with CLL and steroid refractory autoimmune cytopenias such as autoimmune hemolytic anemia and pure red cell aplasia.
A phase 2 trial found that ibrutinib plus rituximab demonstrated efficacy among patients with CLL and steroid refractory autoimmune cytopenias such as autoimmune hemolytic anemia and pure red cell aplasia.
A phase 2 trial found that...
09/21/2023
Oncology
News
Epcoritamab Yields High Overall and Complete Response Rates for Patients With R/R CD20+ LBCL
03/15/2023
According to a phase 1/2 study, CD3-CD20 bispecific t-cell engaging antibody epcoritamab resulted in high overall response and complete response rates profile among patients with R/R CD20+ large b-cell lymphoma.
According to a phase 1/2 study, CD3-CD20 bispecific t-cell engaging antibody epcoritamab resulted in high overall response and complete response rates profile among patients with R/R CD20+ large b-cell lymphoma.
According to a phase 1/2 study,...
03/15/2023
Oncology
News
Addition of Pembrolizumab to Ifosfamide, Carboplatin, and Etoposide Chemotherapy Among Patients With R/R Classic Hodgkin Lymphoma
04/06/2023
According to findings of a phase 2 trial, the addition of pembrolizumab to ifosfamide, carboplatin, and etoposide (ICE) chemotherapy yielded tolerable results among patients with R/R classic Hodgkin lymphoma.
According to findings of a phase 2 trial, the addition of pembrolizumab to ifosfamide, carboplatin, and etoposide (ICE) chemotherapy yielded tolerable results among patients with R/R classic Hodgkin lymphoma.
According to findings of a phase...
04/06/2023
Oncology
News
FDA Grants Accelerated Approval to Talquetamab for Patients With R/R Multiple Myeloma
08/10/2023
On August 9, 2023, the FDA granted accelerated approval to talquetamab for adult patients with relapsed/refractory MM who received 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38...
On August 9, 2023, the FDA granted accelerated approval to talquetamab for adult patients with relapsed/refractory MM who received 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38...
On August 9, 2023, the FDA...
08/10/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD logo
December 9 ⁠–⁠ December 11
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use